Incidental Liver Lesions Evaluation

Initial Triage and Consultation

• For incidental liver lesions, consultation should be directed to radiology for advanced imaging characterization, with the specific imaging modality determined by lesion size, initial imaging findings, and patient risk factors, as recommended by the American College of Radiology 1
• The consultation pathway depends critically on three clinical scenarios that determine malignancy risk, including normal liver, known extrahepatic malignancy, and chronic liver disease/cirrhosis, according to the American College of Radiology 2, 1
• Benign lesions, such as hemangioma, cysts, and focal nodular hyperplasia, occur in up to 15% of the general population and are the most likely diagnosis in patients with a normal liver, as stated by the American College of Radiology 3, 1
• In patients with known extrahepatic malignancy, metastatic disease must be excluded, though benign lesions still occur in nearly 30% of cancer patients, as reported by the American College of Radiology 3, 1
• In patients with chronic liver disease/cirrhosis, hepatocellular carcinoma becomes the primary concern for lesions ≥10 mm, particularly with elevated tumor markers and lesions >2 cm, according to the American College of Radiology 1

Imaging Modalities and Diagnostic Accuracy

• MRI with contrast establishes a definitive diagnosis in 95% of liver lesions, significantly higher than CT, and only 1.5% require further imaging versus 10% with CT, as reported by the American College of Radiology 4
• Gadoxetate-enhanced MRI achieves 95-99% accuracy for hemangioma, 88-99% for focal nodular hyperplasia, and 97% for hepatocellular carcinoma, according to the American College of Radiology 5, 4
• CEUS reaches a specific diagnosis in 83% of indeterminate lesions and distinguishes benign from malignant in 90% of cases, as stated by the American College of Radiology 1
• Multiphase contrast-enhanced CT correctly differentiates malignant from benign lesions in 74-95% of cases, as reported by the American College of Radiology 2

Lesion Size and Context-Based Consultation

• For lesions >1 cm in normal liver patients, refer to radiology for one of three equivalent first-line options: multiphase contrast-enhanced CT, MRI with and without IV contrast, or contrast-enhanced ultrasound (CEUS), as recommended by the American College of Radiology 2, 1
• For lesions >1 cm in patients with known malignancy, refer to radiology for MRI with contrast or multiphase CT, with FDG-PET/CT as an additional equivalent option when initially found on noncontrast imaging, according to the American College of Radiology 1
• For lesions >1 cm in chronic liver disease/cirrhosis, refer to radiology for Liver Imaging Reporting and Data System (LI-RADS) evaluation using triple-phase contrast CT (arterial, portal venous, delayed) as the preferred option, as stated by the American College of Radiology 1

Biopsy Consultation and Risks

• Refer to interventional radiology for percutaneous image-guided biopsy only when imaging features indicate possible malignancy or when lesions such as lymphoma require histopathologic diagnosis, as recommended by the American College of Radiology 5, 4
• Avoid biopsy of solid benign liver lesions such as hemangiomas or focal nodular hyperplasia by obtaining diagnostic CT or MRI first, according to the American College of Radiology 5
• CEUS guidance increases the technical success rate from 74% to 100% for biopsy of indeterminate lesions, as reported by the American College of Radiology 5, 4
• Postbiopsy bleeding risk is 9-12%, particularly with hypervascular lesions, and a small risk of needle-track seeding exists, as stated by the American College of Radiology 5, 4

Imaging Strategy for a 3 cm Solid Liver Lesion Detected on Ultrasound

Preferred Imaging Modality

• Multiphasic contrast‑enhanced MRI (with and without IV contrast) is the imaging modality of choice for a 3 cm solid liver lesion, offering superior lesion characterization and higher diagnostic accuracy than CT. [6][7]

Recommendations by Clinical Scenario

Patients with a Normal Liver (No Known Malignancy or Chronic Liver Disease)

• First‑line imaging should be multiphasic contrast‑enhanced MRI, which provides a definitive diagnosis in approximately 95 % of liver lesions. 7
• When MRI is unavailable or contraindicated, contrast‑enhanced ultrasound (CEUS) is an acceptable alternative, achieving a specific diagnosis in about 83 % of indeterminate lesions and correctly distinguishing benign from malignant lesions in roughly 90 % of cases. 7

Patients with Known Extra‑hepatic Malignancy

• Either contrast‑enhanced MRI or multiphase CT may be used as the initial test to exclude metastatic disease; both modalities have comparable performance. 7
• In this population, MRI demonstrates a sensitivity of 90.8 %–95.4 % and a specificity of 83.7 %–89.8 % for detecting malignant lesions. 7
• FDG‑PET/CT is an equivalent option when the lesion was first identified on non‑contrast imaging. 7

Patients with Chronic Liver Disease or Cirrhosis

• Triple‑phase contrast‑enhanced CT (arterial, portal venous, delayed) or dynamic contrast‑enhanced MRI interpreted with LI‑RADS criteria should be employed for non‑invasive HCC diagnosis. [6][7]
• Extracellular contrast agents are preferred over gadoxetic acid for MRI‑based HCC diagnosis; for 1‑2 cm HCC, sensitivity is 71 % and specificity 83 % with extracellular agents. 6
• Application of LI‑RADS refines lesion categorization (including LR‑M and LR‑TIV) and provides an estimated probability of HCC in at‑risk nodules. 6

Advantages of MRI Over CT

• MRI provides superior lesion characterization, with sensitivity 71 % and specificity 83 % for 1‑2 cm lesions versus 70 % and 81 % for CT, respectively. 6
• MRI avoids ionizing radiation and adds diffusion‑weighted imaging for enhanced tissue characterization. 8

Role of Contrast‑Enhanced Ultrasound (CEUS)

• CEUS correctly characterizes 95 % of lesions overall and 98 % of metastases in patients with indeterminate CT findings. 7
• CEUS reduces indeterminate diagnoses by 67 % and yields sensitivity 90.2 % and specificity 80.8 % for focal liver lesion characterization. 7

Indications for Image‑Guided Biopsy

• Percutaneous biopsy should be reserved for lesions with inconclusive imaging or when histopathology is required for molecular testing; LI‑RADS category 5 lesions can be diagnosed non‑invasively with near‑100 % specificity. 9
• Post‑biopsy bleeding risk is 9 %–12 %, and needle‑tract seeding occurs in 0.1 %–0.9 % per year for HCC. 9

Common Pitfalls to Avoid

• Single‑phase CT or non‑contrast imaging is inadequate for solid liver lesion characterization and should not be ordered. 7
• LI‑RADS criteria must not be applied to patients without chronic liver disease or cirrhosis. 6
• Ultrasound alone is insufficient for solid lesion characterization compared with cross‑sectional imaging modalities. [8][10]

Imaging Diagnosis and Management of Incidental Liver Hemangioma

Initial CT Evaluation

Advanced Imaging When CT Is Indeterminate

Clinical History Considerations

Biopsy Recommendations

Management of Non‑Biopsied Liver Metastases on Triple‑Phase CT

Diagnostic Approach

• For patients with a suspected liver metastasis on triple‑phase CT, proceed directly to a multidisciplinary tumor‑board discussion without routine biopsy because imaging alone is sufficient for treatment planning and biopsy adds significant risk without altering management. 13
• In individuals with a known primary malignancy, roughly 91 % of liver lesions are malignant, yet ≈30 % of lesions in cancer patients are benign, underscoring the need for careful imaging characterization. 13
• The presence of chronic liver disease or cirrhosis shifts the differential diagnosis toward hepatocellular carcinoma rather than metastatic disease. 14

Biopsy Decision‑Making

• Routine biopsy is not recommended when imaging demonstrates typical metastatic features in a patient with a known primary tumor, as imaging alone reliably guides treatment planning. [14][13]
• Biopsy should be avoided for lesions that are deemed resectable and slated for surgical treatment because it does not change management and carries a 9–12 % risk of bleeding. 13
• Biopsy of small lesions has a ≈30 % false‑negative rate and a needle‑track seeding risk of 0.1–0.7 %. 13
• Image‑guided biopsy is indicated only when imaging remains indeterminate after MRI or when histopathology is required for molecular testing to select systemic therapy. 13
• Biopsy is required when the differential includes lymphoma or other malignancies that need histopathologic confirmation for appropriate therapy. 13
• In about 5 % of cases, imaging may suggest a different primary cancer than the known one; biopsy is needed to clarify the diagnosis. 13
• Using contrast‑enhanced ultrasound (CEUS) guidance increases the technical success rate of biopsy for indeterminate lesions from roughly 74 % to 100 %. 13
• Biopsy of hypervascular lesions carries a 9–12 % bleeding risk and should be performed only after a careful risk‑benefit assessment. 13

Treatment Planning Considerations

• Treatment planning should not be delayed while awaiting biopsy confirmation when imaging already provides a definitive diagnosis in patients with a known primary malignancy. 14
• Up to 30 % of liver lesions in cancer patients are benign; accurate imaging characterization is essential to avoid unnecessary treatment. 13